Which statement would require follow up at a staff conference on neurologic treatments?

• A. Clients with MS often receive immunoglobulin G (IVIG).
• B. Immunomodulatory therapy is not used for MS
• C. Baclofen is used for spasticity management
• D. Vaccinations are contraindicated in MS

Answer: (A)

Understanding how multiple sclerosis is typically treated helps you spot statements that would need follow-up. In MS, the standard approach is disease-modifying therapies that modulate the immune system to reduce relapses and slow progression. Immunomodulatory therapies are indeed used for MS, and baclofen is a common medication for managing spasticity, so those points align with established practice. Vaccinations are generally not contraindicated in MS; they are usually encouraged, with considerations only for specific immunosuppressive states.

The statement that would require follow-up at a staff conference is that clients with MS often receive immunoglobulin G (IVIG). IVIG is not a standard or routine disease-modifying therapy for MS, though it may be used in certain immune-related conditions. This is the item that would prompt a review of current guidelines to confirm what therapies are evidence-based for MS and to correct any misconceptions.